Please assess the completion status of the following clinical trial:

Trial Title: Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Required tumor parameters for node positive disease: NOTE: This study will continue to use the American Joint Committee on Cancer (AJCC) 5th edition for TNM classification and staging~  * Operable, histologically confirmed adenocarcinoma of the female breast and positive lymph nodes~    * Node positivity may be determined by either an axillary node dissection or a positive sentinel node finding by hematoxylin and eosin (H\&E)~      * NOTE: Positive nodes refers to H\&E visible nodal metastases; immunohistochemistry (IHC) positive only cells in lymph nodes will not be considered positive nodes~   * One or more positive lymph nodes whose tumors are T1-3, pN1-2, M0 are eligible~   * cN2 disease is not eligible~   * pN2 disease is eligible~   * One positive lymph node by sentinel node biopsy or at least 6 axillary nodes must be examined on axillary node dissection with at least one positive lymph node~   * Metaplastic carcinoma is eligible~ * ER/PgR determination~ * HER-2 positive (pre-entry requirement for registration)~    * FISH must show gene amplification OR~   * IHC assay must show a strong positive (3+) staining score~      * NOTE: ductal carcinoma in situ (DCIS) components should not be counted in the determination of degree of IHC staining or FISH amplification~* Required tumor parameters for high-risk node-negative disease; NOTE: This study will continue to use the AJCC 5th edition for TNM classification and staging~  * Operable, histologically confirmed adenocarcinoma of the female breast and negative lymph nodes~    * Node status may be determined by either axillary node dissection or sentinel node biopsy with H\&E staining; to be considered node negative, either of the following must be true: 1) negative sentinel node biopsy or 2) no positive lymph nodes found among at least 6 axillary nodes examined on axillary node dissection~   * NOTE: IHC positive only cells in lymph nodes will not be considered positive nodes~   * Tumors \> 2.0 cm (irrespective of hormonal receptor status) or \> 1.0 cm if ER-negative and PR-negative disease~ * ER/PgR determination~ * HER-2 positive (pre-entry requirement for registration)~    * FISH must show gene amplification OR~   * IHC assay must show a strong positive (3+) staining score~      * NOTE: DCIS components should not be counted in the determination of degree of IHC staining or FISH amplification~* =\< 84 days from mastectomy or =\< 84 days from axillary dissection or sentinel node detection if the patient's most extensive breast surgery was a breast sparing procedure; (This timing is per a decision by the Breast Intergroup)~* Surgical resection margins. All tumor should be removed by either a modified radical mastectomy or a segmental mastectomy with axillary node dissection~  * Mastectomy: There will be no evidence of gross or microscopic tumor (invasive or DCIS) at the surgical resection margins noted in the final surgery or pathology reports; patients with close margins are eligible~ * Segmental mastectomy (lumpectomy): Margins must be clear of invasive cancer and DCIS~ * Axillary dissection or sentinel node dissection: There will be no gross residual adenopathy~* TAM therapy~  * May have received up to four weeks of TAM therapy, or any other hormonal agent, for this malignancy~ * May have received TAM or raloxifene for purposes of chemoprevention (e.g., Breast Cancer Prevention Trial) or for other indications (including previous breast cancer if lobular carcinoma in situ \[LCIS\]) but must be discontinued before registration on this study~ * May never have received TAM, raloxifene, or any other hormonal agent~* Absolute neutrophil count (ANC) \>= 1500/mm\^3~* Platelets (PLT) \>= 100,000/mm\^3~* Total bilirubin =\< 1.5 x upper normal limit (UNL)~* Aspartate aminotransferase (AST) =\< 2.0 x UNL~* Left ventricular ejection fraction (LVEF) within institutional normal range; if LVEF is \> 75%, the investigator should consider performing a second review of the multigated acquisition (MUGA)/echocardiogram or performing a repeat MUGA/echocardiogram prior to registration; such re-reviews or repeat MUGA/echocardiogram are not permitted after registration~* Willingness to discontinue sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc., prior to registration and while on study~* Willingness to discontinue any hormonal agent such as raloxifene (Evista) prior to registration and while on study~* Non-breast malignancies that have not recurred within the last 5 years and are deemed to be at low risk for recurrence~EXCEPTIONS: These non-breast malignancies are eligible even if diagnosed =\< 5 years prior to registration:~* Squamous or basal cell carcinoma of the skin that has been effectively treated~* Carcinoma in situ of the cervix that has been treated by surgery only~* Lobular carcinoma in situ (LCIS) of the ipsilateral or contralateral breast treated by surgery and/or tamoxifen only~  * Patients undergoing breast conservation therapy (i.e., lumpectomy and axillary dissection) must have plans to receive radiation therapy to the breast +/- regional lymphatics following completion of the chemotherapy; for patients treated with mastectomy, the use of radiation therapy is required for 4 or more positive lymph nodes and must be started after completion of chemotherapy; the use of radiation therapy is at the discretion of the investigator for 0-3 positive lymph nodes but, if used, must be started after the completion of chemotherapy~ * Prior to registration, the physician must designate if it is planned for the patient to receive radiation therapy (for adjuvant radiation therapy post-mastectomy or, less commonly, post-conservative therapy but not primary breast radiation as part of breast conserving treatment)~ * Willing and able to sign an informed consent~ * Gene amplified by FISH or strong positivity (3+) by HercepTest on central review; Note: The patient registers based on community HER-2 testing using FISH or IHC, AC chemotherapy is initiated; the tumor block or slides must be received =\< 2 weeks from time of registration to the North Central Cancer Treatment Group (NCCTG) Operations Office for central HER-2 testing~Exclusion Criteria:~* Any of the following:~  * Pregnant women~ * Nursing women~ * Women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, intrauterine device \[IUD\], surgical sterilization, or abstinence, etc.); hormonal birth control methods are not permitted~* Locally advanced tumors (classification T4) at diagnosis including tumors fixed to chest wall, peau d'orange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid edge)~* Prior history of breast cancer, except LCIS~* Bilateral invasive carcinoma, either metachronous or synchronous (EXCEPTION: Patients diagnosed with unilateral invasive carcinoma and metachronous or synchronous DCIS of the contralateral breast treated with mastectomy are eligible)~* Prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancer~* Active, unresolved infection~* Active cardiac disease~  * Any prior myocardial infarction~ * History of documented congestive heart failure (CHF)~ * Current use of digitalis or beta-blockers for CHF~ * Any prior history of arrhythmia or cardiac valvular disease requiring medications or clinically significant~ * Current use of medications for treatment of arrhythmias or angina pectoris~ * Current uncontrolled hypertension (diastolic \> 100 mmHg or systolic \> 200 mmHg)~ * Clinically significant pericardial effusion~* Prior anthracycline or taxane therapy for any malignancy~* Sensitivity to benzyl alcohol~* Neurology/Neuropathy-Sensory \>= grade 2 per the National Cancer Institute's (NCI's) Common Toxicity Criteria Version 2.0; EXCEPTION: Any chronic neurologic disorder will be looked at on a case-by-case basis by the study chair

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor) (Type: EXPERIMENTAL): Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 20-30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel IV over 1 hour beginning on day 1 of week 13 and continuing weekly for 12 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
- Arm II (AC, paclitaxel, trastuzumab, tamoxifen) (Type: EXPERIMENTAL): Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in arm I. Patients then receive trastuzumab (Herceptin®) IV over 30-90 minutes beginning on day 1 of week 25 and continuing weekly for 52 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
- Arm III (AC, paclitaxel, trastuzumab, tamoxifen) (Type: EXPERIMENTAL): Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I. Patients then receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes beginning on day 1 of week 13 and continuing weekly for 12 courses. Patients then receive trastuzumab IV over 30 minutes beginning on day 1 of week 25 and continuing weekly for 40 courses in the absence of disease progression or unacceptable toxicity.~Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).